Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SB-480848. GlaxoSmithKline.

David P Rotella1

  • 1Lexicon Pharmaceuticals, 350 Carter Road, Princeton, NJ 08540, USA. drotella@lexpharma.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to "Potent, Selective Pyrrolopyrimidine PDE11A4 Inhibitors with Improved Pharmaceutical Properties".

ACS medicinal chemistry letters·2026
Same author

Potent, Selective Pyrrolopyrimidine PDE11A4 Inhibitors with Improved Pharmaceutical Properties.

ACS medicinal chemistry letters·2026
Same author

Versatile Imidazole Scaffold with Potent Activity against Multiple Apicomplexan Parasites.

ACS infectious diseases·2025
Same author

First Demonstration of <i>In Vivo</i> PDE11A4 Target Engagement for Potential Treatment of Age-Related Memory Disorders.

Journal of medicinal chemistry·2024
Same author

Correction to "Structure-Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials".

Journal of medicinal chemistry·2024
Same author

Structure-Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials.

Journal of medicinal chemistry·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

SB-480848 is a new drug targeting lipoprotein-associated phospholipase A2. This inhibitor is being investigated for its potential to treat atherosclerosis, with Phase II trials currently in progress.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Atherosclerosis is a chronic inflammatory disease characterized by plaque buildup in arteries.
  • Lipoprotein-associated phospholipase A2 (Lp-PLA2) is implicated in the inflammatory processes of atherosclerosis.
  • Inhibiting Lp-PLA2 may offer a therapeutic strategy for managing atherosclerosis.

Purpose of the Study:

  • To evaluate the safety and efficacy of SB-480848, a novel Lp-PLA2 inhibitor.
  • To explore the therapeutic potential of SB-480848 in patients with atherosclerosis.

Main Methods:

  • SB-480848 is a reversible inhibitor of lipoprotein-associated phospholipase A2.
  • Clinical trials are being conducted to assess the drug's performance.

Related Experiment Videos

Main Results:

  • Phase II trials are currently underway to gather data on SB-480848.
  • Results from these trials will determine the drug's viability for atherosclerosis treatment.

Conclusions:

  • SB-480848 represents a potential new therapeutic agent for atherosclerosis.
  • Ongoing clinical trials are critical for establishing the clinical utility of this Lp-PLA2 inhibitor.